CLDX Celldex Therapeutics Inc.

2.51
0  0%
Previous Close 2.51
Open 2.55
Price To Book 0.34
Market Cap 37,696,696
Shares 15,018,604
Volume 98,743
Short Ratio
Av. Daily Volume 151,948

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data ASCO June 1, 2019 noted 2/19 CRs + one PR.
CDX-3379
Recurrent/metastatic head and neck squamous cell cancer
Phase 1/2 data presented November 17, 2018 at the Society for Neuro-oncology (SNO) Meeting.
Varlilumab and nivolumab
Solid tumors - cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b data released April 16, 2018 - primary endpoint not met.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 presentation at AACR April 15, 2018.
CDX-301
Non-small Cell Lung Cancer (NSCLC)
Phase 1 updated data at AACR April 1, 2019.
CDX-1140
Solid tumors